Last reviewed · How we verify
DHEA treatment — Competitive Intelligence Brief
phase 3
Steroid hormone / Hormone replacement
Androgen receptor, Estrogen receptor (indirect via metabolite conversion)
Endocrinology / Aging / Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
DHEA treatment (DHEA treatment) — University Hospital, Bordeaux. DHEA (dehydroepiandrosterone) is an endogenous steroid hormone precursor that acts as a substrate for the synthesis of androgens and estrogens, modulating hormonal balance and immune function.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DHEA treatment TARGET | DHEA treatment | University Hospital, Bordeaux | phase 3 | Steroid hormone / Hormone replacement | Androgen receptor, Estrogen receptor (indirect via metabolite conversion) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Steroid hormone / Hormone replacement class)
- University Hospital, Bordeaux · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DHEA treatment CI watch — RSS
- DHEA treatment CI watch — Atom
- DHEA treatment CI watch — JSON
- DHEA treatment alone — RSS
- Whole Steroid hormone / Hormone replacement class — RSS
Cite this brief
Drug Landscape (2026). DHEA treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/dhea-treatment. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing